Acitretin

Acitretin is an oral retinoid medicine that the ChEMBL database records as a small molecule with a retinoid receptor agonist mechanism, approved for psoriasis. ChEMBL gives its first approval as 1996 and its highest development phase as 4, which means it has reached the market, and the World Health Organization classification places it at ATC code D05BB02 in the dermatologicals group. Its adopted name carries the stem -retin, which the United States Adopted Names programme defines as retinol derivatives, and the name was adopted in 1987. ChEMBL flags a boxed warning for the drug, and it records the drug as an oral product, not a parenteral or topical one. This entry records what the sources state and is not medical advice.